(NYSE:CMBT),(Brussels:CMBT),(Oslo Bors:CMBTO), Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) provides a market update. During Q3 and Q4 to date, CMB.TECH has continued its fleet rejuvenation strategy with the sale of two older vessels and the delivery of five newbuild vessels. Fleet update […]

PRESS RELEASE: CMB.TECH trading update GlobeNewswire October 20, 2025 Antwerp, Oct. 20, 2025 (GLOBE NEWSWIRE) — CMB.TECH NV (NYSE: CMBT, Euronext Brussels: CMBT and Euronext Oslo Børs: CMBTO) (“CMB.TECH”) provides a market update. During Q3 and Q4 to date, CMB.TECH has continued its fleet rejuvenation strategy with the sale of two older vessels and the

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstCytokinetics, Incorporated (“Cytokinetics” or “the Company”) (NASDAQ: CYTK) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's

NEW YORK CITY, NY / ACCESS Newswire / October 20, 2025 / NEW YORK, NY / ACCESS Newswire / October 20, 2025 / If you suffered a loss on your Tronox Holdings plc (NYSE:TROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

NEW YORK CITY, NY / ACCESS Newswire / October 20, 2025 / NEW YORK, NY / ACCESS Newswire / October 20, 2025 / If you suffered a loss on your Fly-E Group, Inc. (NASDAQ:FLYE) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information:

At the 2025 European Society for Medical Oncology (ESMO) Congress, a Phase III clinical study on disitamab vedotin plus toripalimab versus chemotherapy as first-line treatment for HER2-expressing locally advanced or metastatic urothelial carcinoma (RC48-C016) sponsored by RemeGen Co., Ltd. was presented at the Presidential Symposium by Professor Jun Guo from Beijing Cancer Hospital. It's the

A drug that harnesses the immune system to attack cancer cells has proved successful in preventing a rare and aggressive form of skin cancer from spreading to other organs when given immediately after surgery, a new study shows. https://mma.prnewswire.com/media/2329447/NYU_Langone_Health_Logo1.jpg Led by researchers at NYU Langone Health and its Perlmutter Cancer Center, the study is the

TheSchall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstNutex Health Inc. (“Nutex” or “the Company”) (NASDAQ: NUTX) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's

The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit againstPubMatic, Inc. (“PubMatic” or “the Company”) (NASDAQ: PUBM) forviolations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission. https://mma.prnewswire.com/media/1396534/Schall_Firm_Logo.jpg Investors who purchased the Company's

The Co-Creation Workshop: October 19, EXEED held its New Product Co-Creation Workshop under the theme “Shift to Tomorrow” at REBOX. The spot was the New Venue of the Old Shipyard 1900. The Workshop brought the global debut of its new family design language and the industry-leading Texxeract new energy technology. Texxeract Technology Launch: The newly